Lundbeck
Lundbeck, officially known as H. Lundbeck A/S, is a global pharmaceutical company headquartered in Denmark (DK). Founded in 1915, Lundbeck has established itself as a leader in the neuroscience sector, focusing on the treatment of brain disorders such as depression, schizophrenia, and Alzheimer's disease. With a strong presence in Europe, North America, and Asia, the company is dedicated to improving the lives of patients through innovative therapies. Lundbeck's core products include a range of unique medications that address complex neurological conditions, setting them apart in a competitive market. The company has achieved notable milestones, including the development of several breakthrough treatments that have significantly impacted patient care. Renowned for its commitment to research and development, Lundbeck continues to strengthen its position as a key player in the global pharmaceutical industry.
DitchCarbon Score
How does Lundbeck's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lundbeck's score of 72 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lundbeck's reported carbon emissions
In 2024, Lundbeck reported total greenhouse gas emissions of approximately 11,464,000 kg CO2e for Scope 1 and about 2,068,000 kg CO2e for Scope 2, resulting in a combined total of around 13,532,000 kg CO2e for these two scopes. In 2023, the company recorded similar emissions, with Scope 1 at about 11,314,000 kg CO2e and Scope 2 at approximately 1,845,000 kg CO2e, leading to a total of around 13,159,000 kg CO2e. Lundbeck has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 63% by 2034 from a 2019 baseline. Additionally, the company targets a 19% reduction in absolute Scope 3 emissions by the same year. Near-term goals include a 42% reduction in Scope 1 and 2 emissions by 2029, alongside a 25% reduction in Scope 3 emissions within the same timeframe. Furthermore, Lundbeck is committed to achieving net-zero emissions across its value chain by 2050. To support these targets, Lundbeck plans to exclusively utilise 100% renewable electricity for all EU sites by 2025, demonstrating a proactive approach to sustainability in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lundbeck is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
